Bergqvist A, Kullander S, Thorell J
Acta Obstet Gynecol Scand Suppl. 1981;101:75-81. doi: 10.3109/00016348109157817.
ER and PR were assayed in 13 malignant and 20 benign ovarian tumors of different histologic types. ER was detectable in 67% and PR in 40% of the malignant tumors, compared with 35 and 45% in the benign tumors, respectively. The ER concentration was somewhat higher in the malignant lesions but there was no difference in the PR level. A retrospective review of 39 primary ovarian tumors of different pathologic stages and classes, treated postoperatively with medroxyprogesterone acetate (MPA, Depo-Provera, UpJohn) and in most cases Melphalan, showed a high Karnofsky performance index and good complete and partial response rates. The need for a prospective, controlled study of the role of MPA treatment of malignant ovarian tumors in evident.
对13例不同组织学类型的恶性卵巢肿瘤和20例良性卵巢肿瘤进行了雌激素受体（ER）和孕激素受体（PR）检测。恶性肿瘤中67%可检测到ER，40%可检测到PR，相比之下，良性肿瘤中ER和PR的检测率分别为35%和45%。恶性病变中的ER浓度略高，但PR水平无差异。回顾性分析39例不同病理分期和类型的原发性卵巢肿瘤，这些患者术后接受醋酸甲羟孕酮（MPA，安宫黄体酮，UpJohn公司生产）治疗，多数病例还联合美法仑治疗，结果显示患者卡氏功能状态指数较高，完全缓解和部分缓解率良好。显然有必要对MPA治疗恶性卵巢肿瘤的作用进行前瞻性对照研究。
